Represents the percentage of net loss from commercialization.

No definition available.

Name:	irwd_CollaborativeArrangementPercentageOfNetLoss
Namespace Prefix:	irwd_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the percentage of net profit from commercialization.

+ References

No definition available.

+ Details

Name:	irwd_CollaborativeArrangementPercentageOfNetProfit
Namespace Prefix:	irwd_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Contingent sales-related milestone receivable.

+ References

No definition available.

+ Details

Name:	irwd_ContingentSalesRelatedMilestoneReceivable
Namespace Prefix:	irwd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the cumulative amount of license fees and milestone payments received to date.

+ References

No definition available.

+ Details

Name:	irwd_LicenseFeesAndMilestonePaymentReceivedCumulative
Namespace Prefix:	irwd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents net cost sharing offset amounts related to collaborative arrangement where a cost sharing agreement exists for research and development expenses. Amounts may net to either a reduction of expense, or may net to increased expense.

+ References

No definition available.

+ Details

Name:	irwd_NetCostSharingOffsetRelatedToResearchAndDevelopmentExpenseReimbursement
Namespace Prefix:	irwd_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Number of milestone payments received.

+ References

No definition available.

+ Details

Name:	irwd_NumberOfMilestonePaymentsReceived
Namespace Prefix:	irwd_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of Remaining Commercial Period Performance Obligations.

+ References

No definition available.

+ Details

Name:	irwd_NumberOfRemainingCommercialPeriodPerformanceObligations
Namespace Prefix:	irwd_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585

+ Details

Name:	us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	irwd_AchievementOfMilestoneAxis=irwd_SalesMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=irwd_AbbviePlcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	irwd_AchievementOfMilestoneAxis=irwd_DevelopmentAndSalesMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	irwd_AchievementOfMilestoneAxis=irwd_DevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=srt_NorthAmericaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration, License, Co-Promotion and Other Commercial Agreements - North America - General Information (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020 USD ($)	Jun. 30, 2019 USD ($)	Jun. 30, 2020 USD ($) item payment	Jun. 30, 2019 USD ($)
Collaboration, License and Co-Promotion Agreements
Research and development expense	$ 22,076	$ 28,758	$ 50,103	$ 60,956
Sales milestones
Collaboration, License and Co-Promotion Agreements
Sales-related milestone if certain conditions are met	100,000		100,000
AbbVie
Collaboration, License and Co-Promotion Agreements
Equity investment in the entity's capital stock			25,000
Research and development expense	500		$ 1,200
Net cost sharing offset or incremental expense related to research and development expense		2,400		5,600
Remaining commercial-period performance obligations \| item			3
AbbVie \| Development and sales milestones
Collaboration, License and Co-Promotion Agreements
Cumulative license fees and development milestone payments received	205,000		$ 205,000
AbbVie \| Development milestones
Collaboration, License and Co-Promotion Agreements
Number of milestone payments received \| payment			6
AbbVie \| Sales milestones
Collaboration, License and Co-Promotion Agreements
Percentage of net profit from commercialization (as a percent)			50.00%
Percentage of net loss from commercialization (as a percent)			50.00%
North America \| AbbVie
Collaboration, License and Co-Promotion Agreements
Research and development expense	$ 6,200	$ 9,600	$ 12,900	$ 19,600